Results:
We included 20 patients presented with shingles (one of whom had Ramsay
Hunt Syndrome RHS). The sex ratio (M/F) was 0.8. The median age was 68.5
years (ranging between 22 and 80 years). Nine patients had a minimum age
of 70 years. The administered vaccines were an mRNA vaccine for 15
patients, a viral vector vaccine for four patients, and an inactivated
vaccine for one patient. Symptomatology occurred after the first dose of
an mRNA vaccine in 10 patients, and in two patients after the second
dose of the viral vector vaccines. The symptoms delay ranged from one
day to 30 days (mean of 4.5 days). Four patients had a medical history
of diabetes. No concomitant use of immunosuppressants was reported for
all patients. All patients recovered within a few days and no severe
cases were reported.
An 80-year-old patient with a medical history of colorectal neoplasia
received an inactivated vaccine and got the second dose without
recurrence of the event. Another patient presented facial paralysis with
aggravation of the initial symptomatology (vesicular rash of the left
auricle one week after receiving his first dose) three days after
receiving the second dose of mRNA vaccine; noting that the initial
symptomatology was not entirely disappeared when the patient received
the second dose. This patient was diagnosed with Ramsay Hunt Syndrome.